Experimental drug targets tough blood cancers in first human trial
NCT ID NCT05673057
Summary
This study is testing a new drug called MP0533 for the first time in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see if it helps control these blood cancers. The trial will include up to 249 adults whose cancer has returned or hasn't responded to previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HP Hôpital Saint-Louis
RECRUITINGParis, 75010, France
-
Amsterdam UMC - Locatie VUmc
RECRUITINGAmsterdam, Netherlands
-
CHU Bordeaux
RECRUITINGBordeaux, France
-
Erasmus MC
RECRUITINGRotterdam, Netherlands
-
Groningen UMC
RECRUITINGGroningen, Provincie Groningen, Netherlands
-
IUCT Oncopole
RECRUITINGToulouse, France
-
Inselspital, Universitaetsspital Bern
RECRUITINGBern, Canton of Bern, 3010, Switzerland
-
Universitaetsspital Zuerich
RECRUITINGZurich, Canton of Zurich, 8006, Switzerland
-
Vilnius University Hospital Santaros Klinikos
RECRUITINGVilnius, Lithuania
Conditions
Explore the condition pages connected to this study.